OPKO Health (NASDAQ:OPK) Issues Quarterly Earnings Results

OPKO Health (NASDAQ:OPK) issued its earnings results on Thursday. The biotechnology company reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.03, Zacks reports. The firm had revenue of $148.50 million for the quarter, compared to the consensus estimate of $139.76 million. OPKO Health had a negative return on equity of 17.30% and a negative net margin of 37.19%.The company’s revenue was down 19.1% compared to the same quarter last year. During the same quarter last year, the business posted $0.01 EPS.

Here are the key takeaways from OPKO Health’s conference call:

• OPKO completed a second major asset sale of BioReference’s oncology assets and repositioned BioReference as a streamlined, regionally focused clinical lab with a national 4Kscore franchise, which management says positions the diagnostics business for sustained profitable growth in 2026.
• The company struck a collaboration with Regeneron (potentially >$1 billion in milestones plus royalties) and has an EBV vaccine partnership with Merck, providing non-dilutive funding and external development/commercial support for ModeX programs.
• ModeX clinical progress: MDX-2001 has dosed >25 patients with dose escalation showing tolerability and early efficacy signals, MDX-2004 (immune rejuvenator) and MDX-2003 (CD19/CD20 tetraspecific) are in/entering Phase 1, and multiple readouts/phase advances are expected through 2026.
• OPKO entered 2026 with a strong liquidity position (reported $369 million in cash/restricted cash) and an active buyback program (34.6M shares repurchased in 2025; ~$113M remaining authorization), which management is using alongside R&D investments.
• Financial headwinds remain as Q4 revenue declined to $148.5M (from $183.6M) after the divestiture, Q4 net loss was $31.3M, and full-year 2026 guidance implies heavy spending with total costs of $725M–$750M driven by increased R&D investment.

OPKO Health Price Performance

Shares of NASDAQ:OPK remained flat at $1.20 during trading on Friday. The stock had a trading volume of 3,826,552 shares, compared to its average volume of 2,379,331. OPKO Health has a one year low of $1.11 and a one year high of $2.04. The stock has a fifty day moving average price of $1.27 and a two-hundred day moving average price of $1.36. The company has a debt-to-equity ratio of 0.25, a quick ratio of 3.32 and a current ratio of 3.70. The stock has a market capitalization of $921.24 million, a price-to-earnings ratio of -4.00 and a beta of 1.47.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on OPK. Wall Street Zen raised OPKO Health from a “sell” rating to a “hold” rating in a report on Sunday, December 21st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of OPKO Health in a research note on Thursday, January 22nd. Finally, JPMorgan Chase & Co. initiated coverage on shares of OPKO Health in a report on Thursday, November 20th. They issued a “neutral” rating for the company. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $2.28.

Key Stories Impacting OPKO Health

Here are the key news stories impacting OPKO Health this week:

• Positive Sentiment: Q4 beat — OPKO reported a $0.04 loss per share vs. a consensus loss of $0.07 and revenue of $148.5M versus ~$139.8M expected, which likely supported the uptick. OPK Q4 Earnings & Revenues Beat Estimates, Gross Margin Contracts
• Positive Sentiment: High-value Regeneron collaboration — OPKO’s ModeX unit struck a multispecific-antibody deal with Regeneron (upfront + milestones; program-level potential >$200M and overall collaboration value >$1B), adding substantial upside if programs advance. OPKO Health, Inc. Reports Q4 2025 Financial Results and 2026 Guidance
• Positive Sentiment: Pipeline progress — several programs advanced: MDX2003 cleared for Phase 1 in Australia, MDX2001/2004 abstracts presented at major conferences, and Merck completed a Phase 1 EBV vaccine trial. These developmental milestones de-risk parts of the biologics pipeline. OPKO Health Reports Fourth Quarter 2025 Business Highlights and Financial Results
• Positive Sentiment: Balance sheet & buybacks — OPKO ended 2025 with ~$369M in cash and has repurchased ~$87M of stock under its program, leaving ~ $112.7M available, which supports shareholder-return optionality. OPKO Health Reports Fourth Quarter 2025 Business Highlights and Financial Results
• Neutral Sentiment: Investor access — management will hold one-on-one meetings at the Jefferies Biotech on the Beach Summit (Mar 10–11), which could provide more investor detail but is routine IR activity. OPKO Health to Participate in the Jefferies Biotech on the Beach Summit
• Negative Sentiment: Top-line pressure — consolidated revenue declined ~19% YoY to $148.5M (partly from asset sales) and diagnostics/service revenue dropped materially, which pressures near-term growth expectations. OPKO Health Reports Fourth Quarter 2025 Business Highlights and Financial Results
• Negative Sentiment: Margins & losses — gross margin contraction, higher costs (R&D and SG&A) and an operating loss drove a $31.3M net loss for Q4, highlighting ongoing profitability challenges. OPK Q4 Earnings & Revenues Beat Estimates, Gross Margin Contracts
• Negative Sentiment: Guidance vs. Street — OPKO guided 2026 revenue to $530–560M (Q1: $125–140M), below some consensus figures cited by analysts, which could cap upside until execution visibility improves. OPKO Health, Inc. Reports Q4 2025 Financial Results and 2026 Guidance

Hedge Funds Weigh In On OPKO Health

Hedge funds have recently added to or reduced their stakes in the stock. Geode Capital Management LLC raised its stake in shares of OPKO Health by 0.6% in the fourth quarter. Geode Capital Management LLC now owns 11,061,318 shares of the biotechnology company’s stock worth $13,940,000 after purchasing an additional 67,973 shares during the last quarter. Millennium Management LLC raised its holdings in shares of OPKO Health by 39.2% in the first quarter. Millennium Management LLC now owns 6,386,911 shares of the biotechnology company’s stock valued at $10,602,000 after purchasing an additional 1,798,385 shares during the last quarter. Goldman Sachs Group Inc. raised its holdings in shares of OPKO Health by 150.9% in the fourth quarter. Goldman Sachs Group Inc. now owns 5,986,913 shares of the biotechnology company’s stock valued at $7,544,000 after purchasing an additional 3,600,378 shares during the last quarter. AQR Capital Management LLC lifted its position in shares of OPKO Health by 466.7% during the first quarter. AQR Capital Management LLC now owns 1,608,906 shares of the biotechnology company’s stock valued at $2,671,000 after purchasing an additional 1,324,988 shares in the last quarter. Finally, HRT Financial LP purchased a new position in OPKO Health during the fourth quarter worth about $851,000. Institutional investors and hedge funds own 64.63% of the company’s stock.

OPKO Health Company Profile

OPKO Health, Inc (NASDAQ:OPK) is a diversified, global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals and biologics development. The company operates two main business segments—Laboratory Services and Pharma Services & Products—driven by its mission to advance patient care through innovation in testing and targeted therapies.

In its Laboratory Services segment, OPKO leverages BioReference Laboratories, one of the largest full-service commercial labs in the United States.